Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Proof-of-Concept Clinical Trial to Evaluate the Efficacy of Ketotifen and Indomethacin for Mild and Moderate COVID-19 in Adults

NCT05007522 is registered in ClinicalTrials.gov with Sen-Jam Pharmaceutical as lead sponsor.

NCT NCT05007522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05007522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Proof-of-Concept Clinical Trial to Evaluate the Efficacy of Ketotifen and Indomethacin for Mild and Moderate COVID-19 in Adults
Lead sponsor
Sen-Jam Pharmaceutical
Phase
Phase 3
Overall status
Completed
Start date
May 3, 2022
Completion date
June 20, 2024
Enrollment
150 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 respiratory infection